This was the best abstract at ASH 2022 (IMO). It is now fully published: acpjournals.org/doi/10.7326/M2… Take-home message: Don't routinely order SPEP/light chains in pts with auto-immune diseases, and share with paper with your rheumatology colleagues! Stellar work! iStopMM

Looking forward to the myeloma #mmsm abstracts at #ASCO24. Here is a list of what I'll be paying closest attention to! 🧵

Randomized trials are for yesterday ?? I agree that cancer patients need early access to drugs but at the same time , drugs with marginal benifits and more toxicities are of no use to cancer patients. In countries, where patients have to pay from there own pockets, financial

Did you know that somatic mutations are also common in T cells and they impact their function? Please read further details from our new paper in Science Advances Congratulations for excellent work Sofie Lundgren and whole team! Medicine and Health, University of Helsinki science.org/doi/10.1126/sc…

Definitely read Dr Prasad’s 🧵 I will try to put in layman’s terms why this matters:

THL suhtautuu kriittisesti yksityisten palveluiden Kela-korvausten nostoon. Yksityisen palvelutuotannon resursseja pitäisi hyödyntää osana hyvinvointialueiden toimintaa. #sote #perusterveydenhuolto thl.fi/-/thl-kehittai…

Earlier this week, Michelle and I called our friend Kamala Harris. We told her we think she’ll make a fantastic President of the United States, and that she has our full support. At this critical moment for our country, we’re going to do everything we can to make sure she wins in

THIS WINS THE DAY!!!!

Important commentary highlighting the futility of routine MGUS testing in patients with osteoporosis! Especially with iStopMM data showing no association, unnecessary testing leading to medicalizing of healthy patients needs to stop!

🚀🚀🚀 Exciting opportunity! We are hiring a post-doc researcher to work on targeted therapies for T-cell ALL...if you are passionate about innovative treatments, apply now! Please spread the word 🥳🥳🥳 tuni.rekrytointi.com/paikat/?o=A_RJ…

Amid the buzz around treating high-risk smoldering myeloma, do we truly understand its natural history in the modern era? Manni Mohyuddin is answering this with the SPOTLIGHT trial-a decentralized prospective study on active surveillance with local labs & WB DW-MRI. Remote enrollment

Killer road map for in vivo CAR T cell #immunotherapy 👇

hs.fi/mielipide/art-… Lukusuositus. Asiantuntijat: Lääkkeiden teho tutkittava satunnaistetuilla vertailevilla lääketutkimuksilla. Oikotiet voivat johtaa negatiiviseen lopputulokseen, kun tehoa ei ole ja kustannukset vievät resursseja muilta tehokkaammilta toimilta.

This was an amazing effort and practice changing study for LGL leukemia - cyclophosphamide is superior to MTX with respect to ORR with comparable safety - took 10 years to accrue but shows can do RCT in rare hem diseases #EHA25 #EHA2025

🧬 Real-World CAR-T in RRMM: Cilta-cel vs Ide-cel 💥 🇩🇪 Nationwide registry of 343 RRMM pts (≥3 prior lines): 🆚 Cilta-cel (n=77) vs Ide-cel (n=266) ✅ Cilta-cel superior: •ORR: 94% vs 82% •CR: 61% vs 39% •10-mo PFS: 76% vs 47% •Better CR conversion, esp. in PR/SD pts ⚠️

No They Don't

🔥 Hot off the press: In a new study, Cooperrider et al., show that lenalidomide drives expansion of high-risk TP53-mutant clones, which may predispose MM patients to secondary blood cancers like t-MDS and t-ALL. Caner Saygin, MD ⁦ Ben Derman University of Chicago Hematology/Oncology ow.ly/gvMO50WqIjj

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML ashpublications.org/bloodneoplasia… #AML #leusm

“Stem cell boost was associated with a near doubling of PFS in patients who received ide-cel” Classic example of immortal time bias A patient has to be alive to receive a stem cell boost (and have enough marrow reserve to successfully collect stem cells) #ASH25 #mmsm